查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1944411

全球人工智慧药物定序市场：按治疗领域、药物类型、最终用户、部署方法、国家和地区划分－产业分析、市场规模、份额和预测（2025-2032年）

Artificial Intelligence In Drug Repurposing Market, By Therapeutic Area, By Drug Type, By End User, By Deployment Mode, By Country, and By Region -Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 374 Pages | 商品交期: 2-3个工作天内

价格
简介目录

预计到 2024 年，人工智慧 (AI) 药物定序市场规模将达到 9.9098 亿美元，从 2025 年到 2032 年的复合年增长率将达到 20.10%。

人工智慧在现有药物定序的应用是指运用智慧计算系统分析大型、复杂的生物医学资料集，从而发现现有药物的新用途。它利用机器学习、深度学习和自然语言处理等人工智慧技术，揭示药物、标靶和疾病之间潜在的关联。这些人工智慧驱动的工具能够加速药物发现过程，降低研发成本，并提高识别潜在治疗药物的成功率。数据分析和假设产生的自动化能够提升製药和生技公司的决策效率和研发效率。此外，它还有助于更快地满足未被满足的医疗需求，并实现更易于获取、数据驱动且更具成本效益的药物开发策略。

人工智慧在药物定序的市场动态

人工智慧和机器学习在药物研发的应用日益广泛

人工智慧和机器学习在药物研发领域的日益普及，指的是将先进的计算模型整合到药物发现和开发过程中，以提高研究效率和成果的趋势。这使得分析庞大而复杂的生物医学数据集（包括基因组数据、临床试验结果和科学文献）成为可能，从而更准确地识别新的药物-疾病关联。在利用人工智慧进行药物重定位时，这种应用支援预测建模、目标分子识别以及对现有药物库进行快速筛检，以寻找新的治疗用途。因此，製药公司可以缩短开发週期、降低研发成本，并改善早期研究阶段的决策。此外，人工智慧和机器学习加强了跨数位研究平台的协作，实现了来自多个来源的无缝资料整合。它还支援透过真实世界数据和实验数据不断改进和训练模型。总而言之，人工智慧和机器学习的日益普及正在提升现代药物研发生态系统中药物重定位策略的扩充性、可靠性和有效性。例如，根据美国食品药物管理局）的数据，在药物研发的各个阶段，采用人工智慧技术的药物申请数量显着增加，2016年至2023年间记录在案的AI相关申请超过500件。此外，FDA于2025年发布了一份指导文件草案，就如何负责任地使用AI来支持生技药品和生物製品的监管决策提出了建议。此举凸显了FDA积极主动地促进创新，同时在AI辅助药物研发中维持严格的安全性和有效性标准。这显示监管机构和相关机构对将先进的AI和机器学习工具整合到药物研发中给予了强有力的支持。这也反映了更广泛的行业趋势，即数据驱动技术正被越来越多地用于促进药物再利用、提高分析准确性以及优化研发决策。因此，基于AI的方法正在成为一种高效且经济的策略，用于识别新的治疗用途并满足尚未满足的医疗需求。

人工智慧药物定序市场：細項分析

全球药物定序人工智慧市场按治疗领域、药物类型、最终用户、部署模式和地区进行细分。

根据治疗领域，市场可分为三大类：肿瘤学、神经病学和心血管疾病。肿瘤学领域在人工智慧药物定序市场中占据显着份额，因为其能够加速现有抗癌药物新用途的发现。加速肿瘤药物研发需要利用先进技术，透过分析大型资料集、临床试验结果和分子交互作用，缩短识别有效抗癌治疗方法所需的时间。这个过程利用人工智慧演算法、预测建模和机器学习来优化候选药物的选择并简化研究工作流程。加快药物发现速度可以提高研发效率、降低开发成本，并有助于快速提供可能挽救生命的治疗方法。人工智慧驱动的药物重定位透过计算筛检、标靶预测和数据驱动的洞察来实现这一加速，使研究人员能够快速识别、检验和优先排序有前景的肿瘤候选药物。例如，根据世界卫生组织（世卫组织）发布的《2024年全球癌症负担报告》，预计2022年全球将新增2,000万例癌症病例，970万人死于癌症，约有5,350万人能在确诊癌症后的五年内存活。这些数据凸显了全球癌症负担的快速加重，并显示各卫生系统迫切需要改善癌症的预防、早期发现和治疗服务。

根据药物类型，市场可分为两大类：小分子药物和生技药品。小分子药物凭藉其广泛的适用性和完善的安全性记录，在人工智慧药物定序市场中占据最大份额。丰富的历史数据和临床数据为其优势提供了有力支撑，使人工智慧演算法能够高效地分析分子结构、预测标靶相互作用并识别有前景的重定位机会。与从头开始的药物研发相比，该领域能够实现更快、更经济的药物开发，从而更快转化为临床应用。此外，小分子药物还具有许多优势，例如可扩展的人工智慧驱动工作流程、跨多个治疗领域的适用性以及在重定位倡议中取得的稳定结果，使其成为市场关注的焦点。例如，根据《巨量资料驱动医疗保健的重大变革》报告，生物医学和临床数据量正呈指数级增长，PubMed收录的生物医学论文超过2300万篇，仅当年就新增了约100万篇。这反映了研究和临床资讯的快速增长。报导进一步强调，超过80%的医疗保健数据为非结构化数据，包括临床记录和说明记录，凸显了医疗保健数据的规模、种类和复杂性，以及这些数据在研究、分析和数据驱动决策中的应用。这种广泛应用表明，数位化製药和生物医学研究基础设施已日趋成熟。这也反映了更广泛的趋势，即人工智慧驱动的技术正在实现对临床和分子数据的可扩展访问，提高研究平台间的互通性，并扩大人工智慧解决方案在药物重定位和药物发现中的应用。

人工智慧在药物定序市场的应用—区域分析

由于製药研发基础设施、医疗保健体係以及人工智慧技术应用方面的差异，人工智慧药物定序市场呈现出显着的区域差异。北美，尤其是美国和加拿大，在强大的生物技术和製药研究网络、人工智慧驱动的药物再利用平台的广泛应用以及对创新治疗方法的旺盛需求的推动下，市场持续保持强劲增长。欧洲市场也持续稳步扩张，这得益于製药研发投入的增加、监管机构对基于人工智慧的药物开发的支持以及可互通的临床和分子数据系统的整合。在亚太地区，不断成长的製药研究倡议、大规模的患者群体、政府的支持政策以及生物技术公司与学术机构之间的合作，正在为中国、印度、日本和韩国等国家带来显着的市场动力。同时，拉丁美洲以及中东和非洲地区正透过加强临床研究基础设施、改善分子和临床数据集的获取以及提高对人工智慧驱动的药物再利用解决方案的认知度，逐步巩固其市场地位。

美国人工智慧药物定序市场—国家分析

在美国强大的製药和生物技术基础以及人工智慧药物发现平台日益普及的推动下，美国药物定序人工智慧市场正稳步发展。研究机构、生物技术公司和製药公司正越来越多地利用人工智慧来发现现有药物的新用途、优化研发流程并加速临床开发进程。主要技术供应商的加入以及监管机构对人工智慧驱动药物开发的支持进一步推动了市场成长。此外，提高效率、降低开发成本和加快治疗方法上市速度的趋势也加速了美国製药业对人工智慧药物重定位解决方案的采用。

根据英国政府加速人工智慧驱动药物研发的计划，英国将支持OpenBind联盟，目标是在五年内产生超过50万个实验性蛋白质-配体复合物结构和亲和性测量数据，相当于过去50年产生的公共数据总量的20倍。这项由政府资助和战略合作推动的计划，旨在扩展高品质的生物医学数据集，并加速英国人工智慧驱动的药物研发。

目录

第一章 人工智慧药物定序市场概述

  • 分析范围
  • 市场估算期

第二章执行摘要

  • 市场区隔
  • 竞争考察

第三章 人工智慧在药物定序的关键市场趋势

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 未来市场趋势

第四章 人工智慧在药物定序市场的应用：产业分析

  • PEST分析
  • 波特五力分析
  • 市场成长展望：概览
  • 管理体制分析

第五章 人工智慧在药物定序市场的应用：地缘政治紧张局势加剧的影响

  • 新冠疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章 人工智慧在药物定序的市场现状

  • 人工智慧药物定序市场份额分析（2024 年）
  • 主要製造商的细分数据
    • 对现有公司的分析
    • 新兴企业分析

7. 人工智慧在药物定序市场（依治疗领域划分）

  • 概述
    • 细分市场占有率分析：依治疗领域划分
    • 代谢性疾病
    • 瘤
    • 罕见疾病
    • 感染疾病
    • 神经病学
    • 免疫学
    • 循环系统疾病
    • 其他的

第八章 人工智慧在药物定序市场的应用（按药物类型划分）

  • 概述
    • 细分市场占有率分析：依药物类型划分
    • 胜肽
    • 疫苗
    • 低分子化合物
    • 生技药品
    • 其他的

9. 人工智慧在药物定序市场的应用（依最终用户划分）

  • 概述
    • 细分市场占有率分析：依最终用户划分
    • 医疗保健提供者
    • 学术和研究机构
    • 製药和生物技术公司
    • 受託研究机构（CRO）
    • 其他的

第十章 人工智慧在药物定序的市场应用（以部署方式划分）

  • 概述
    • 细分市场占有率分析：依药物类型划分
    • 本地部署
    • 基于云端的

第十一章 区域药物定序人工智慧市场

  • 介绍
  • 北美洲
    • 概述
    • 北美主要製造商
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲主要製造商
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 其他的
  • 亚太地区
    • 概述
    • 亚太地区主要製造商
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 其他的
  • 拉丁美洲
    • 概述
    • 拉丁美洲主要製造商
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 其他的
  • 中东和非洲（MEA）
    • 概述
    • 中东和非洲的主要製造商
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • 其他的

第十二章 主要供应商分析：人工智慧在药物定序产业的应用

  • 竞争对手仪錶板
    • 竞争基准
    • 竞争定位
  • 公司简介
    • Cyclica Inc.
    • BioAge Labs, Inc.
    • BostonGene Corporation
    • Insilico Medicine, Inc.
    • Healx Ltd.
    • Ignota Labs Ltd.
    • Atomwise, Inc.
    • Ginkgo Bioworks Holdings, Inc.
    • United Therapeutics Corporation
    • Recursion Pharmaceuticals, Inc.
    • TxGNN, Inc.
    • Exscientia plc
    • BioXcel Therapeutics, Inc.
    • BenevolentAI Limited
    • Melior Discovery, Inc.
    • Others

第十三章：分析师视角360度分析

简介目录
Product Code: ANV6014

Artificial Intelligence In Drug Repurposing Market size was valued at US$ 990.98 Million in 2024, expanding at a CAGR of 20.10% from 2025 to 2032.

Artificial Intelligence in Drug Repurposing refers to the application of intelligent computational systems that identify new therapeutic uses for existing drugs by analyzing large, complex biomedical datasets. It leverages artificial intelligence technologies, such as machine learning, deep learning, and natural language processing, to uncover hidden relationships among drugs, targets, and diseases. These AI-driven tools help accelerate drug discovery timelines, reduce development costs, and improve the success rate of identifying viable treatment candidates. By automating data analysis and hypothesis generation, they enhance decision-making and research efficiency within pharmaceutical and biotechnology organizations. Artificial intelligence in drug repurposing also supports faster responses to unmet medical needs and enables more accessible, data-driven, and cost-effective drug development strategies.

Artificial Intelligence In Drug Repurposing Market- Market Dynamics

Increasing adoption of AI and machine learning in pharmaceutical R&D

Increasing adoption of AI and machine learning in pharmaceutical R&D refers to the growing integration of advanced computational models within drug discovery and development processes to improve research efficiency and outcomes. It enables the analysis of vast and complex biomedical datasets, including genomic data, clinical trial results, and scientific literature, to identify novel drug disease relationships with greater accuracy. In artificial intelligence driven drug repurposing, this adoption supports predictive modeling, target identification, and rapid screening of existing drug libraries for new therapeutic applications. As a result, pharmaceutical companies are able to reduce development timelines, lower R&D costs, and improve decision-making in early-stage research. Moreover, AI and machine learning enhance collaboration across digital research platforms, enabling seamless data integration from multiple sources. They also support continuous model refinement and learning through real-world and experimental data. Overall, the increasing use of AI and machine learning strengthens the scalability, reliability, and effectiveness of drug repurposing strategies in modern pharmaceutical R&D ecosystems. For example, according to the U.S. Food and Drug Administration's Center for Drug Evaluation and Research (CDER), the number of drug application submissions incorporating artificial intelligence has risen markedly across the drug development lifecycle, with over 500 AI-related submissions recorded between 2016 and 2023. In addition, the FDA released draft guidance in 2025 providing recommendations on the responsible use of AI to support regulatory decision-making for drug and biological products. This development highlights the FDA's proactive approach to encouraging innovation while maintaining rigorous standards for safety and efficacy in AI-enabled drug development. This underscores solid regulatory and institutional backing for the integration of advanced AI and machine learning tools within pharmaceutical research and development. It also reflects wider industry trends where data-driven technologies are being increasingly adopted to accelerate drug repurposing, enhance analytical accuracy, and optimize R&D decision-making. Consequently, AI-enabled approaches are emerging as efficient and cost-effective strategies for identifying new therapeutic applications and addressing unmet medical needs.

Artificial Intelligence In Drug Repurposing Market- Segmentation Analysis:

The Global Artificial Intelligence in Drug Repurposing Market is segmented by Therapeutic Area, Drug Type, End User, Deployment Mode, and Region.

The market is divided into three categories based on Therapeutic Area Oncology, Neurology, and Cardiovascular Diseases. The Oncology segment represents a significant portion of the Artificial Intelligence in Drug Repurposing market due to its capacity to speed up the discovery of new therapeutic uses for existing cancer drugs. Accelerating drug discovery in oncology involves using advanced technologies to reduce the time required to identify effective cancer treatments by analyzing extensive datasets, clinical trial outcomes, and molecular interactions. This process leverages AI-powered algorithms, predictive modeling, and machine learning to optimize candidate selection and streamline research workflows. Shortening discovery timelines improves R&D efficiency, lowers development costs, and enables faster delivery of potentially life-saving therapies. In AI-driven drug repurposing, this acceleration is achieved through computational screening, target prediction, and data-driven insights, allowing researchers to rapidly identify, validate, and prioritize promising oncology drug candidates. For instance, according to the World Health Organization's 2024 report on the global cancer burden, an estimated 20 million new cancer cases and 9.7 million cancer-related deaths occurred worldwide in 2022, with approximately 53.5 million people living within five years of a cancer diagnosis. These figures underscore the rapidly increasing global cancer burden and highlight the urgent need for improved prevention, early detection, and treatment services across healthcare systems.

The market is divided into two categories based on Drug Type: Small Molecule Drugs and Biologics. The Small Molecule Drugs segment accounts for the largest share of the Artificial Intelligence in Drug Repurposing market, driven by its extensive applicability and well-documented safety profiles. Its dominance is supported by the availability of rich historical and clinical data, which allows AI algorithms to efficiently analyze molecular structures, predict target interactions, and identify promising repurposing opportunities. This segment enables faster and more cost-effective drug development compared with new drug discovery, supporting quicker clinical translation. Additionally, small molecules benefit from scalable AI-driven workflows, applicability across multiple therapeutic areas, and consistent outcomes in repurposing initiatives, making them a key focus in the market. For instance, according to the Big Data in Medicine is Driving Big Changes, the volume of biomedical and clinical data has grown exponentially, with over 23 million biomedical articles indexed in PubMed, and nearly one million new publications added that year alone, reflecting the rapidly increasing availability of research and clinical information. The article also highlights that more than 80 % of healthcare data is unstructured, including clinical notes and narrative records, underscoring the scale, diversity, and complexity of medical data now being generated and leveraged for research, analysis, and data-driven decision-making. This extensive adoption underscores the maturity of digital pharmaceutical and biomedical research infrastructure. It reflects broader trends in which AI-driven technologies are enabling scalable access to clinical and molecular data, improved interoperability across research platforms, and the expanded use of AI-based solutions for drug repurposing and discovery.

Artificial Intelligence In Drug Repurposing Market- Geographical Insights

The Artificial Intelligence in Drug Repurposing market demonstrates significant regional variation, influenced by differences in pharmaceutical R&D infrastructure, healthcare systems, and AI technology adoption. North America continues to exhibit strong activity, supported by robust biotech and pharmaceutical research networks, widespread use of AI-driven drug repurposing platforms, and high demand for innovative therapeutics, particularly in the U.S. and Canada. Europe is witnessing consistent expansion, backed by growing investments in pharmaceutical research, regulatory support for AI-based drug development, and integration of interoperable clinical and molecular data systems. In Asia Pacific, increasing pharmaceutical research initiatives, large patient populations, supportive government policies, and partnerships between biotech firms and academic institutions are contributing to notable market momentum in countries such as China, India, Japan, and South Korea. Meanwhile, Latin America, the Middle East, and Africa are gradually strengthening their market presence through enhanced clinical research infrastructure, improved access to molecular and clinical datasets, and growing awareness of AI-enabled drug repurposing solutions.

United States Healthcare Virtual Assistant Market - Country Insights

The United States Artificial Intelligence in Drug Repurposing market is advancing steadily, fueled by a strong pharmaceutical and biotech infrastructure and the growing adoption of AI-powered drug discovery platforms. Research institutions, biotech firms, and pharmaceutical companies are increasingly using AI to uncover new therapeutic applications for existing drugs, optimize R&D workflows, and accelerate clinical development timelines. Engagement from leading technology providers, along with regulatory support for AI-driven drug development, is further promoting market growth. Moreover, the emphasis on improving efficiency, reducing development costs, and bringing therapies to market faster is accelerating the uptake of AI-enabled drug repurposing solutions across the U.S. pharmaceutical sector.

According to a UK Government announcement on advancing AI-driven drug discovery, the UK aims to support the OpenBind consortium in generating over 500,000 experimental protein-ligand complex structures and affinity measurements over five years, marking a 20-fold increase compared with all public data produced over the past 50 years. This effort is backed by government funding and strategic collaborations to expand high-quality biomedical datasets and accelerate AI-enabled drug research and development across the country.

Artificial Intelligence In Drug Repurposing Market- Competitive Landscape:

The Artificial Intelligence in Drug Repurposing market is moderately concentrated, with a number of leading pharmaceutical, biotech, and AI-focused technology companies driving competition. Prominent players include IBM Watson Health, Exscientia, Insilico Medicine, Healx, BenevolentAI, Recursion Pharmaceuticals, Atomwise, Evotec, BioAge Labs, Cyclica, Schrodinger, and In Silico Trials. These companies compete by providing AI-powered platforms that identify new therapeutic applications for existing drugs, streamline R&D processes, predict drug-target interactions, and accelerate clinical development timelines. They differentiate themselves through capabilities such as deep learning-driven drug discovery, large-scale biomedical data analytics, integration with research databases, and cloud-based computational platforms, enabling faster, more efficient, and cost-effective drug repurposing.For example, in 2023, Exscientia entered a multi-target collaboration with Merck KGaA, leveraging its AI-powered drug discovery platform to accelerate the design of novel therapeutics, with an upfront payment of USD 20 million and potential milestone payments exceeding USD 670 million. By 2024, Exscientia further expanded its platform capabilities through a partnership with Amazon Web Services (AWS), enabling cloud-based computational drug design and large-scale data analytics. The market is driven by rising demand for efficient, data-driven, and AI-enabled drug repurposing solutions, particularly in oncology and rare diseases. Additionally, companies are enhancing their platforms with predictive modeling, deep learning algorithms, and cloud-based deployments to meet the growing need for faster, cost-effective, and precise identification of new therapeutic applications for existing drugs.

Recent Developments:

In November 2024, Recursion Pharmaceuticals completed a business combination with Exscientia, creating a unified AI-powered drug discovery platform that integrates both companies' technologies and pipelines to advance drug discovery and development with enhanced computational capabilities. This combined entity features more than 10 clinical and preclinical programs and aims to reduce discovery timelines and costs through iterative AI-driven research loops.

In July 2024, Insilico Medicine announced a collaboration with Inimmune to leverage its proprietary AI platform, Chemistry42, to accelerate the discovery and development of future immunotherapeutics, marking a strategic expansion of its AI-based drug design capabilities into novel therapeutic areas and reinforcing the role of AI in identifying and optimizing drug candidates.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG REPURPOSING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Cyclica Inc.
  • BioAge Labs, Inc.
  • BostonGene Corporation
  • Insilico Medicine, Inc.
  • Healx Ltd.
  • Ignota Labs Ltd.
  • Atomwise, Inc.
  • Ginkgo Bioworks Holdings, Inc.
  • United Therapeutics Corporation
  • Recursion Pharmaceuticals, Inc.
  • TxGNN, Inc.
  • Exscientia plc
  • BioXcel Therapeutics, Inc.
  • BenevolentAI Limited
  • Melior Discovery, Inc.
  • Others

GLOBALARTIFICIAL INTELLIGENCE IN DRUG REPURPOSING MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032

  • Metabolic Disorders
  • Oncology
  • Rare Diseases
  • Infectious Diseases
  • Neurology
  • Immunology
  • Cardiovascular Diseases
  • Others

GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG REPURPOSING MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Peptides
  • Vaccines
  • Small Molecules
  • Biologics
  • Others

GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG REPURPOSING MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Healthcare Providers
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Others

GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG REPURPOSING MARKET, BY DEPLOYMENT MODE- MARKET ANALYSIS, 2019 - 2032

  • On-premises
  • Cloud-based

GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG REPURPOSING MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Artificial Intelligence In Drug Repurposing Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Artificial Intelligence In Drug Repurposing Market Snippet by Therapeutic Area
    • 2.1.2. Artificial Intelligence In Drug Repurposing Market Snippet by Drug Type
    • 2.1.3. Artificial Intelligence In Drug Repurposing Market Snippet by End User
    • 2.1.4. Artificial Intelligence In Drug Repurposing Market Snippet by Deployment Mode
    • 2.1.5. Artificial Intelligence In Drug Repurposing Market Snippet by Country
    • 2.1.6. Artificial Intelligence In Drug Repurposing Market Snippet by Region
  • 2.2. Competitive Insights

3. Artificial Intelligence In Drug Repurposing Key Market Trends

  • 3.1. Artificial Intelligence In Drug Repurposing Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Artificial Intelligence In Drug Repurposing Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Artificial Intelligence In Drug Repurposing Market Opportunities
  • 3.4. Artificial Intelligence In Drug Repurposing Market Future Trends

4. Artificial Intelligence In Drug Repurposing Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Artificial Intelligence In Drug Repurposing Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Artificial Intelligence In Drug Repurposing Market Landscape

  • 6.1. Artificial Intelligence In Drug Repurposing Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Artificial Intelligence In Drug Repurposing Market - By Therapeutic Area

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Therapeutic Area, 2024&2032 (%)
    • 7.1.2. Metabolic Disorders
    • 7.1.3. Oncology
    • 7.1.4. Rare Diseases
    • 7.1.5. Infectious Diseases
    • 7.1.6. Neurology
    • 7.1.7. Immunology
    • 7.1.8. Cardiovascular Diseases
    • 7.1.9. Others

8. Artificial Intelligence In Drug Repurposing Market - By Drug Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Type, 2024&2032 (%)
    • 8.1.2. Peptides
    • 8.1.3. Vaccines
    • 8.1.4. Small Molecules
    • 8.1.5. Biologics
    • 8.1.6. Others

9. Artificial Intelligence In Drug Repurposing Market - By End User

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End User, 2024&2032 (%)
    • 9.1.2. Healthcare Providers
    • 9.1.3. Academic & Research Institutes
    • 9.1.4. Pharmaceutical & Biotechnology Companies
    • 9.1.5. Contract Research Organizations (CROs)
    • 9.1.6. Others

10. Artificial Intelligence In Drug Repurposing Market - By Deployment Mode

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Drug Type, 2024&2032 (%)
    • 10.1.2. On-premises
    • 10.1.3. Cloud-based

11. Artificial Intelligence In Drug Repurposing Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024&2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Artificial Intelligence In Drug Repurposing Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Artificial Intelligence In Drug Repurposing Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Artificial Intelligence In Drug Repurposing Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APACMarket Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 11.4.5. APACMarket Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.4.6. APACMarket Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.7. APACMarket Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. PhilippinesMarket Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.15.4. PhilippinesMarket Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.15.5. PhilippinesMarket Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.4.15.6. PhilippinesMarket Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Artificial Intelligence In Drug Repurposing Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAMMarket Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAMMarket Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAMMarket Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAMMarket Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Artificial Intelligence In Drug Repurposing Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEAMarket Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 11.6.5. MEAMarket Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.6.6. MEAMarket Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.7. MEAMarket Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. IsraelMarket Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.10.4. IsraelMarket Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.10.5. IsraelMarket Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.6.10.6. IsraelMarket Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Artificial Intelligence In Drug Repurposing Industry

  • 12.1. Competitive Benchmarking
    • 12.1.1. Competitive Dashboard
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Cyclica Inc.
    • 12.2.2. BioAge Labs, Inc.
    • 12.2.3. BostonGene Corporation
    • 12.2.4. Insilico Medicine, Inc.
    • 12.2.5. Healx Ltd.
    • 12.2.6. Ignota Labs Ltd.
    • 12.2.7. Atomwise, Inc.
    • 12.2.8. Ginkgo Bioworks Holdings, Inc.
    • 12.2.9. United Therapeutics Corporation
    • 12.2.10. Recursion Pharmaceuticals, Inc.
    • 12.2.11. TxGNN, Inc.
    • 12.2.12. Exscientia plc
    • 12.2.13. BioXcel Therapeutics, Inc.
    • 12.2.14. BenevolentAI Limited
    • 12.2.15. Melior Discovery, Inc.
    • 12.2.16. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us